Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox

ClinicalTrials.gov ID: NCT00668304

Public ClinicalTrials.gov record NCT00668304. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial Eradication and Key Symptom Relief in the Treatment of Acute Bacterial Maxillary Sinusitis With Moxifloxacin 400 mg QD

Study identification

NCT ID: NCT00668304
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Bayer; Industry
Enrollment: 192 participants

Conditions and interventions

Conditions

Maxillary Sinusitis

Interventions

Avelox (Moxifloxacin, BAY12-8039) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2004
Primary completion: Not listed
Completion: Dec 31, 2004
Last update posted: Dec 18, 2014

2004 – 2005

United States locations

U.S. sites: 29
U.S. states: 19
U.S. cities: 29

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35206	—
Not listed	Hoover	Alabama	35216-5453	—
Not listed	Jonesboro	Arkansas	72401	—
Not listed	Searcy	Arkansas	72143	—
Not listed	Fresno	California	93720	—
Not listed	Riverside	California	92506	—
Not listed	San Francisco	California	94102	—
Not listed	Colorado Springs	Colorado	80909	—
Not listed	Longmont	Colorado	80501	—
Not listed	Bridgeport	Connecticut	06606	—
Not listed	DeLand	Florida	32720-2560	—
Not listed	Shreveport	Louisiana	71105	—
Not listed	Detroit	Michigan	48202	—
Not listed	North Massapequa	New York	11758	—
Not listed	Rochester	New York	14618	—
Not listed	Columbus	Ohio	43235	—
Not listed	Oklahoma City	Oklahoma	73120	—
Not listed	Yukon	Oklahoma	73099	—
Not listed	Lake Oswego	Oregon	97035	—
Not listed	Harrisburg	Pennsylvania	17110	—
Not listed	Greenville	South Carolina	29607	—
Not listed	Orangeburg	South Carolina	29118	—
Not listed	Jackson	Tennessee	38301	—
Not listed	Carrollton	Texas	75010	—
Not listed	Salt Lake City	Utah	84102	—
Not listed	Charlottesville	Virginia	22902	—
Not listed	Richmond	Virginia	23229	—
Not listed	Winchester	Virginia	22601	—
Not listed	Spokane	Washington	99202-1334	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00668304, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 18, 2014 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00668304 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →